{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:52:34Z","timestamp":1784735554109,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016924","name":"National Cerebral and Cardiovascular Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006004","name":"Tohoku University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006004","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IJC Heart & Vasculature"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ijcha.2025.101863","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T03:52:48Z","timestamp":1767757968000},"page":"101863","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Association of elevated cyclic GMP levels with hemodynamic changes in HFrEF patients treated with sacubitril\/valsartan and vericiguat: a pilot study"],"prefix":"10.1016","volume":"62","author":[{"given":"Takumi","family":"Inoue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Takahama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taijyu","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Yaoita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Nochioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Tatebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Minamino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcha.2025.101863_b0005","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.pharmthera.2009.02.009","article-title":"Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics","volume":"122","author":"Tsai","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ijcha.2025.101863_b0010","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1253\/circj.CJ-12-0664","article-title":"Cyclic GMP-dependent signaling in cardiac myocytes","volume":"76","author":"Takimoto","year":"2012","journal-title":"Circ. J."},{"key":"10.1016\/j.ijcha.2025.101863_b0015","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1161\/01.RES.0000246118.98832.04","article-title":"Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases","volume":"99","author":"Fischmeister","year":"2006","journal-title":"Circ. Res."},{"key":"10.1016\/j.ijcha.2025.101863_b0020","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1161\/01.CIR.96.2.509","article-title":"Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction","volume":"96","author":"Tsutamoto","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.ijcha.2025.101863_b0025","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.122.010111","article-title":"Urinary cGMP (Cyclic Guanosine Monophosphate)\/BNP (B-Type Natriuretic Peptide) ratio, sacubitril\/valsartan, and outcomes in heart failure with reduced ejection fraction: an analysis of the PARADIGM-HF trial","volume":"16","author":"Butt","year":"2023","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.ijcha.2025.101863_b0030","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/ejhf.656","article-title":"Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy","volume":"19","author":"Diez","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcha.2025.101863_b0035","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.jacc.2020.08.031","article-title":"Targeting cyclic guanosine monophosphate to treat heart failure: JACC review topic of the week","volume":"76","author":"Emdin","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcha.2025.101863_b0040","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.792798","article-title":"Cyclic GMP and PKG signaling in heart failure","volume":"13","author":"Numata","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ijcha.2025.101863_b0045","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.cardiores.2004.07.004","article-title":"Left ventricular assist device support reverses altered cardiac expression and function of natriuretic peptides and receptors in end-stage heart failure","volume":"64","author":"Kuhn","year":"2004","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ijcha.2025.101863_b0050","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1016\/S0024-3205(02)01990-2","article-title":"Increased expression of renal neutral endopeptidase in severe heart failure","volume":"71","author":"Knecht","year":"2002","journal-title":"Life Sci."},{"key":"10.1016\/j.ijcha.2025.101863_b0055","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.jacc.2006.10.063","article-title":"Evidence for functional heterogeneity of circulating B-type natriuretic peptide","volume":"49","author":"Liang","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcha.2025.101863_b0060","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1253\/circj.CJ-18-0824","article-title":"Cutting edge of brain natriuretic peptide (BNP) Research - the diversity of BNP immunoreactivity and its clinical relevance","volume":"82","author":"Kuwahara","year":"2018","journal-title":"Circ J"},{"key":"10.1016\/j.ijcha.2025.101863_b0065","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ijcard.2017.12.047","article-title":"Ratio of pro-B-type natriuretic peptide (BNP) to total BNP is decreased in mild, but not severe, acute decompensated heart failure patients: a novel compensatory mechanism for acute heart failure","volume":"258","author":"Takahama","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcha.2025.101863_b0070","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcha.2025.101863_b0075","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcha.2025.101863_b0080","doi-asserted-by":"crossref","DOI":"10.1002\/ehf2.14802","article-title":"Evaluating haemodynamic changes: vericiguat in patients with heart failure with reduced ejection fraction","author":"Suzuki","year":"2024","journal-title":"ESC Heart Fail."},{"key":"10.1016\/j.ijcha.2025.101863_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(25)01682-4","article-title":"Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials","author":"Zannad","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ijcha.2025.101863_b0090","author":"Bozkurt","year":"2021","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.ijcha.2025.101863_b0095","article-title":"JCS\/JHFS 2025 Guideline on diagnosis and treatment of heart failure","volume":"2025","author":"Kitai","year":"2025","journal-title":"Circ. J."},{"key":"10.1016\/j.ijcha.2025.101863_b0100","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jchf.2020.09.013","article-title":"Atrial natriuretic peptide and treatment with sacubitril\/valsartan in heart failure with reduced ejection fraction","volume":"9","author":"Murphy","year":"2021","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.ijcha.2025.101863_b0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053233","article-title":"Direct immunochemiluminescent assay for proBNP and total BNP in human plasma proBNP and total BNP levels in normal and heart failure","volume":"8","author":"Nishikimi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ijcha.2025.101863_b0110","doi-asserted-by":"crossref","first-page":"F697","DOI":"10.1152\/ajprenal.00003.2020","article-title":"Praliciguat inhibits progression of diabetic nephropathy in ZSF1 rats and suppresses inflammation and apoptosis in human renal proximal tubular cells","volume":"319","author":"Liu","year":"2020","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.ijcha.2025.101863_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2018.06.004","article-title":"Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the American Society of Echocardiography","volume":"32","author":"Mitchell","year":"2019","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"10.1016\/j.ijcha.2025.101863_b0120","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jacc.2005.11.030","article-title":"B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure","volume":"47","author":"Iwanaga","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcha.2025.101863_b0125","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1093\/cvr\/cvac125","article-title":"Natriuretic peptide pathways in heart failure: further therapeutic possibilities","volume":"118","author":"Sangaralingham","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ijcha.2025.101863_b0130","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.cardiores.2005.10.001","article-title":"The role of natriuretic peptides in cardioprotection","volume":"69","author":"Nishikimi","year":"2006","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ijcha.2025.101863_b0135","article-title":"Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial","author":"Butler","year":"2025","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcha.2025.101863_b0140","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003601","article-title":"MiR30-GALNT1\/2 axis-mediated glycosylation contributes to the increased secretion of inactive human prohormone for brain natriuretic peptide (proBNP) from failing hearts","volume":"6","author":"Nakagawa","year":"2017","journal-title":"J. Am. Heart Assoc."}],"container-title":["IJC Heart & Vasculature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906725002660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906725002660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T07:51:58Z","timestamp":1777017118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352906725002660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":28,"alternative-id":["S2352906725002660"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcha.2025.101863","relation":{},"ISSN":["2352-9067"],"issn-type":[{"value":"2352-9067","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of elevated cyclic GMP levels with hemodynamic changes in HFrEF patients treated with sacubitril\/valsartan and vericiguat: a pilot study","name":"articletitle","label":"Article Title"},{"value":"IJC Heart & Vasculature","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcha.2025.101863","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101863"}}